International Journal of Pancreatology

, Volume 26, Issue 1, pp 5–21 | Cite as

The potential for gene therapy in pancreatic cancer

  • M. J. Humphreys
  • W. Greenhalf
  • J. P. Neoptolemos
  • P. Ghaneh
Review

Summary

Pancreatic cancer is highly aggressive and is a leading cause of cancer death in the Western world. Currently, there is no effective treatment for this disease; resection is only available to a small fraction of patients and has a marginal effect on overall survival rates. Chemotherapy and radiation also have very limited effects on patient survival. There is clearly a need for new approaches to treatment of such an aggressive disease. Gene therapy is of potential use in the treatment of cancer, and all currently available strategies are discussed with relevance to pancreatic cancer. A key to such strategy is specific delivery and selective gene expression in target cells. Current approaches include replacement of tumor suppressor genes, the use of antisense (AS) oligonucleotides, gene-directed enzyme prodrug therapy (GDEPT), and immunotherapy. The scene is now set for the next phase of development in clinical trials.

Key Words

Gene therapy pancreatic cancer apoptosis K-ras p53 p16 GDEPT immunotherapy antisense oligonucleotides 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kloppel G, Maillet B. Histological typing of pancreatic and periampullary carcinoma. Eur J Surg Oncol 1991; 17: 139–152.PubMedGoogle Scholar
  2. 2.
    Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands; an epidemiological study. Br J Surg 1995; 82: 111–115.PubMedGoogle Scholar
  3. 3.
    Bramhall SR, Neoptolemos JP. Adjuvant treatment of pancreatic cancer, in Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer Molecular and Clinical Advances. Blackwell Science, 1996; pp. 288–307.Google Scholar
  4. 4.
    Smit VT, Boot AJ, Smits AA, Fleuren GJ, Cornelisse CJ, Bos JL. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma. Nucl Acids Res 1988; 16: 7773–7782.PubMedGoogle Scholar
  5. 5.
    Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, et al. Ki-ras oncogene activation in preinvasive pancreatic adenocarcinoma. Gastroenterology 1992; 102: 230–236.PubMedGoogle Scholar
  6. 6.
    Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Kloppel G, et al. Abnormalities of p53 tumour supressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076–1082.PubMedGoogle Scholar
  7. 7.
    Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27–32.PubMedGoogle Scholar
  8. 8.
    Hahn SA, Schutte M, Hogue ATMS, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC-4 a candidate tumour-suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–353.PubMedGoogle Scholar
  9. 9.
    Yamanaka Y, Freiss H, Onda M, Buchler M, Beger HG, Korc M. Co-expression of the epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness. Anticancer Res 1993; 13: 565–569.PubMedGoogle Scholar
  10. 10.
    Yamanaka Y, Freiss H, Kobrin MS, Buchler M, Beger HG, Uchida E, et al. Over-expression of acidic and basic fibroblast growth factors in human pancreatic cancers correlates with advanced tumour stage. Cancer Res 1993; 53: 5289–5296.PubMedGoogle Scholar
  11. 11.
    Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, et al. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 1996; 66: 125–130.PubMedGoogle Scholar
  12. 12.
    Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 1996; 67: 386–392.PubMedGoogle Scholar
  13. 13.
    Nielsen LL, Maneval DC. p53 tumour suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52–63.PubMedGoogle Scholar
  14. 14.
    Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, et al. Adenovirus-mediated wild-type p53 tumour suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998; 5: 681–688.PubMedGoogle Scholar
  15. 15.
    Hwang RF, Gordon EM, Anderson WF, Parekh D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998; 124: 143–151.PubMedGoogle Scholar
  16. 16.
    Ghaneh P, Humphreys M, Greenhalf W, Lemoine N, Neoptolemos JP. p53 and p16 gene therapy results in killing of pancreatic cells. Br J Surg 1998; 85: 1555.Google Scholar
  17. 17.
    Lang D, Miknyoczki SJ, Huang L, Ruggeri BA. Stable reintroduction of wild-type p53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic cancer cells. Oncogene 1998; 16: 1593–1602.PubMedGoogle Scholar
  18. 18.
    Ganly I, Brown R. Onyx-015, and E1B deleted adenovirus, enhances the cytotoxicity to cisplatin and radiation in the functional p53 human ovarian adenocarcinoma cell line A2780. Br J Cancer 1998; 78:610.Google Scholar
  19. 19.
    Hall AR, Dix BR, O’Carroll SJ, Braithwaite AW. p53 dependent cell death-apoptosis is required for a productive adenovirus infection. Nature Med 1998; 4: 1068–1072.PubMedGoogle Scholar
  20. 20.
    Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficiency of cancer therapy in vivo. Science 1994; 266: 807–810.PubMedGoogle Scholar
  21. 21.
    Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wild-type p53 gene. Cancer Res 1994; 54: 2287–2291.PubMedGoogle Scholar
  22. 22.
    Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agents. Int J Cancer 1997; 73: 367–370.PubMedGoogle Scholar
  23. 23.
    Yang B, Eshleman JR, Beger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1997; 2: 1649–1657.Google Scholar
  24. 24.
    Spitz FR, Nguyen D, Skibber JM, Meyn RE, Christiano RJ, Roth JA. Adenoviral mediated wild type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665–1671.PubMedGoogle Scholar
  25. 25.
    Serrano M. Minireview. The tumour suppressor protein p16INK4A. Exp Cell Res 1997; 237: 7–13.PubMedGoogle Scholar
  26. 26.
    Schutte M, Hruban RH, Gradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of Rb/p16 tumour suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126–3130.PubMedGoogle Scholar
  27. 27.
    Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, et al. Effect of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998; 16: 265–272.PubMedGoogle Scholar
  28. 28.
    Lee JH, Lee CT, Yoo CG, Hong YK, Kim CM, Han SK, et al. The inhibitory effect of adenovirus-mediated p16(INK4A) transfer on the proliferation of lung cancer cell line. Anticancer Res 1998; 18: 3257–3261.PubMedGoogle Scholar
  29. 29.
    Grim J, Damico A, Frizelle S, Zhou J, Kratzke RA, Curiel DT. Adenovirus mediated delivery of p16 to p16-deficient human bladder cells confers chemoresistance to cisplatin and paclitaxel. Clin Cancer Res 1997: 3: 2415–2423.PubMedGoogle Scholar
  30. 30.
    Rocco JW, Li DQ, Liggett WH, Duan L, Saunders JK, Sidransky D, et al. p16(INK4A) adenovirus mediated gene therapy for human head and neck squamous cell cancer. Clin. Cancer Res. 1998; 4: 1697–1704.PubMedGoogle Scholar
  31. 31.
    Jin XM, Nguyen D, Zhang WW, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumour-cell proliferation by the p16(INK4A) gene mediated by an adenoviral vector. Cancer Res 1995; 55: 3250–3253.PubMedGoogle Scholar
  32. 32.
    Sheikh MS, Rochefort H, Garcia M. Over-expression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995; 11: 1899–1905.PubMedGoogle Scholar
  33. 33.
    Cardinali M, Jakus J, Shah S, Ensly JF, Robbins KC, Yeudall WA. p21(WAF1/CIP1) retards the growth of human squamous cell carcinoma in vivo. Oral Oncol 1998; 34: 211–218.PubMedGoogle Scholar
  34. 34.
    Joshi US, Chen YQ, Kalemkerian GP, Adil MR, Kraut M, Sarkar FH. Inhibition of tumour cell growth by p21WAF1 adenovirus gene transfer in lung cancer. Cancer Gene Ther. 1998; 5: 183–191.PubMedGoogle Scholar
  35. 35.
    Eastham JA, Hall SJ, Sehgal I, Wang JX, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995; 55: 5151–5155.PubMedGoogle Scholar
  36. 36.
    Matsushita H, Morishita R, Kita I, Aoki M, Hayashi S, Tomita N, et al. Inhibition of growth of human smooth muscle cells by over-expression of p21 gene through induction of apoptosis. Hypertension 1998; 31: 493–498.PubMedGoogle Scholar
  37. 37.
    Joshi US, Dergham ST, Chen YQ, Dugan MC, Crissman JD, Vaitkevicius VK, et al. Inhibition of pancreatic tumour cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 1998; 16: 107–113.PubMedGoogle Scholar
  38. 38.
    Craig C, Wersto R, Kim M, Ohri E, Li ZW, Katayose D, et al. A recombinant adenovirus expressing p27(KIP1) induces cell cycle arrest and loss of cyclin-cyclin dependent kinase activity in human breast cancer cells. Oncogene 1997; 14: 2283–2289.PubMedGoogle Scholar
  39. 39.
    Katayose Y, Kim M, Rakkar ANS, Li ZW, Cowan KH, Seth P. Promoting apoptosis: A novel activity associated with cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57: 5441–5445.PubMedGoogle Scholar
  40. 40.
    Wang XT, Gorospe M, Huang Y, Holbrook NJ. P27(KIP1) over-expression causes apoptotic death of mammalian cells. Oncogene 1997; 15: 2291–2297.Google Scholar
  41. 41.
    Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of the adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorogenicity. Oncogene 1999; 18: 1663–1676.PubMedGoogle Scholar
  42. 41a.
    Schwartze-Waldhoff I, Klein S, Hintelmann A, et al. Suppression of tumoric genicity in colorectal and pancreatic cancer cells by reconstitution of DPC4/SMAD4 is associated with expression changes of invasion, metastasis, and angiogenesis regulators. Gastroenterology 1999; 116: meeting abstract pG2193.Google Scholar
  43. 42.
    Mukhopadhyay T, Roth JA. Antisense regulation of oncogenes in human cancer. Crit Rev Oncogenesis 1996; 7: 151–190.PubMedGoogle Scholar
  44. 43.
    Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1994; 371: 619–622.PubMedGoogle Scholar
  45. 44.
    Liu TH, Li DC, Wang ZY. The inhibitory effect of antisense oligonucleotides on the growth of human pancreatic adenocarcinoma cell lines [in Chinese]. Chin J Pathol 1993; 22: 25–29.Google Scholar
  46. 45.
    Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, et al. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutations but not those without Ki-ras mutations. Mol Carcinog 1997; 20: 251–258.PubMedGoogle Scholar
  47. 46.
    Kita K-I, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999; 80: 553–558.PubMedGoogle Scholar
  48. 47.
    Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumour dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810–3816.PubMedGoogle Scholar
  49. 48.
    Bayever E, Haines KM, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, et al. Selective cytotoxicity to human leukemic myeoblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequence. Leukemia Lymphoma 1993; 12: 223–231.Google Scholar
  50. 49.
    Barton Cm, Lemoine NR. Antisense oligonucleotide directed against p53 have anti-proliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 17: 429–437.Google Scholar
  51. 50.
    Fiedler A, Knorre C, Franke Y, Henne-Bruns D, Kremer B, Luttges J, et al. Growth inhibition of pancreatic tumour cells by modified antisense oligodeoxynucleotides. Langenbeck’s Arch Surg 1998; 383: 269–275.Google Scholar
  52. 51.
    Cai DW, Mukhopadhyay T, Roth JA. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 1995; 2: 199–205.PubMedGoogle Scholar
  53. 52.
    Mukhopadhyay T, Roth JA. A codon 248 mutation retains tumour suppressor function as shown by enhancement of tumour growth by antisense p53. Cancer Res 1993; 53: 4362–4366.PubMedGoogle Scholar
  54. 53.
    Korc M, Chandrasekar B, Yamanaka Y, Freiss H, Buchler MW, Beger HG. Overexpression of EGFR in human pancreatic cancer is associated with concomittant increase in levels of EGF and transforming growth factor alpha. J Clin Invest 1992; 90: 1352–1360.PubMedGoogle Scholar
  55. 54.
    Ebert M, Yokoyama M, Kobrin MS, Freiss H, Lopez ME, Buchler MW, et al. Induction and expression of amphiregullin in human pancreatic cancer. Cancer Res 1994; 54: 3959–3962.PubMedGoogle Scholar
  56. 55.
    Kobrin MS, Funatomi H, Freiss H, Buchler MW, Stathis P. Induction and expression of heparin-binding EGF-growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994; 202: 1705–1709.PubMedGoogle Scholar
  57. 56.
    Yokoyama M, Funatomi H, Kobrin MS, Ebert M, Freiss H, Buchler MW, et al. Betacellulin, a member of the EGF family is overexpressed in human pancreatic cancer. Int J Oncol 1995; 7: 825–829.Google Scholar
  58. 57.
    Funatomi H, Itakura J, Ishiwata I, Pastan I, Thompson SA, Johnson GR, Korc M. Amphiregullin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997; 72: 512–517.PubMedGoogle Scholar
  59. 58.
    Brysch WE, Magal JC, Louis M, Kunst I, Klinger R, Schlingensiepen K, et al. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotide down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumour-cell proliferation. Cancer Gene Ther 1994; 1: 99–105.PubMedGoogle Scholar
  60. 59.
    Palmer Smith J, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cells. Cancer Lett 1999; 135: 107–112.Google Scholar
  61. 60.
    Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumour cells transduced with the cytosine deaminase gene: significant antitumour effect when only a small percentage of tumour cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302–8306.PubMedGoogle Scholar
  62. 61.
    DiMaio JM, Clary BM, Dan FV, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205–213.PubMedGoogle Scholar
  63. 62.
    Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229–238.PubMedGoogle Scholar
  64. 63.
    Yamanaka Y, Freiss H, Kobrin MS, Buchler M, Kunz J, Beger HG, Korc M. Over-expression of Her/neu oncogene in human pancreatic-carcinoma. Hum Pathol 1993; 24: 1127–1134.PubMedGoogle Scholar
  65. 64.
    Ring CJA, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the erbB2 promoter. Gene Ther 1996; 3: 1094–1103.PubMedGoogle Scholar
  66. 65.
    Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, et al. Adenovirus-mediated gene-therapy of hepatocellular carcinoma-chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther 1995; 2: 191–197.Google Scholar
  67. 66.
    DeMatteo RP, McClane SJ, Fisher K, Yeh H, Chu G, Burke C, et al. Engineering tissue-specific expression of a recombinant adenovirus: Selective transgene transcription in the pancreas using the amylase promoter. J Surg Res 1997; 72: 155–161.PubMedGoogle Scholar
  68. 67.
    Ohashi M, Kanai F, Tanaka T, Lan K-H, Shiratori Y, Komatsu Y, et al. In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 1998; 89: 457–462.PubMedGoogle Scholar
  69. 68.
    Carrio M, Romagosa A, Mercade E, Mazo A, Nadal M, GomezFoix AM, et al. Enhanced pancreatic tumour regression by a combination of adenovirus and retrovirusmediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 547–553.PubMedGoogle Scholar
  70. 69.
    Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996; 224: 405–417.PubMedGoogle Scholar
  71. 70.
    Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105–1113.PubMedGoogle Scholar
  72. 71.
    Block A, Chen S-H, Kosai K-I, Finegold M, Woo SLC. Adenovirus-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastases of pancreatic tumours. Pancreas 1997; 15: 25–34.PubMedGoogle Scholar
  73. 72.
    Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumour activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619–4626.PubMedGoogle Scholar
  74. 73.
    Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the E. coli cytosine deaminase gene to human colon carcinoma-derived tumours induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055–1063.PubMedGoogle Scholar
  75. 74.
    Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing E. coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to the liver. Hum Gene Ther 1996; 7: 1567–1576.PubMedGoogle Scholar
  76. 75.
    Evoy D, Hirschowitz EA, Naama HA, Li XK, Crystal RG, Daly JM, et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Sur Res 1997; 69: 226–231.Google Scholar
  77. 76.
    McNeish IA, Green NK, Gilligan MG, Ford MF, Mautner V, Young LS, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using a retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998; 5: 1061–1069.PubMedGoogle Scholar
  78. 77.
    Lohr M, Muller P, Karle P, Stange J, Mitzner S, Jesnowski R, et al. Targeted chemotherapy by intratumoral injection of encapsulated cells engineered to produce CYP2B1, an isofamide activating cytochrome P450. Gene Ther 1998; 5: 1070–1078.PubMedGoogle Scholar
  79. 78.
    Murayama Y, Tadakuma T, Kunitomi M, Kumai K, Tsutsui K, Yasuda T, Kitajima M. Cell specific expression of the diphtheria toxin-A chain coding sequence under the control of upstream region of the human α-fetoprotein gene. J Surg Oncol 1999; 70: 145–149.PubMedGoogle Scholar
  80. 79.
    Cao GW, Qi ZT, Pan X, Zhang XQ, Mia XH, Feng Y, et al. Gene therapy for human colorectal carcinoma using human CEA promoter controlled bacterial ADP-ribosylating toxin genes: pseudomonas exotoxin A and diphtheria toxin A gene transfer. World J Gastroenterol 1998; 4: 388–391.PubMedGoogle Scholar
  81. 80.
    Clary BM, Coveney EC, Philip R, Blazer DG III, Morse M, Gilboa E, et al. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumour cells. Cancer Gene Ther 1997; 4: 97–104.PubMedGoogle Scholar
  82. 81.
    Kimura M, Tagawa M, Takenaga K, Kondo F, Yamaguchi T, Saisho H, et al. Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interleukin-2 or interleukin-4 in nude mice: a potentiality for cancer gene therapy. Cancer Lett 1998; 128: 47–53.PubMedGoogle Scholar
  83. 82.
    Yoshida Y, Tasaki K, Kimurai M, Takenaga K, Yamamoto H, Yamaguchi T, et al. Anti-tumour effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res 1998; 18: 333–336.PubMedGoogle Scholar
  84. 83.
    Sato T, Yamauchi N, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, et al. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumour necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res 1998; 58: 1677–1683.PubMedGoogle Scholar
  85. 84.
    Peplinski GR, Tsung K, Meko JB, Norton JA. In vivo gene therapy of a murine pancreatic tumour with recombinant vaccina virus encoded human interleukin 1 beta. Surgery 1995; 118: 185–191.PubMedGoogle Scholar
  86. 85.
    Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumours for use in clinical trials. Cancer J Sci Am 1998; 4: 194–203.PubMedGoogle Scholar
  87. 86.
    Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumour cells transfected with GM-CSF gene for treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998; 9: 1951–1971.PubMedGoogle Scholar
  88. 87.
    Gjertsen M, Saeserdal I, Thorsby E, Gaudernack G. Characterization of immune response in pancreatic cancer patients after mutant p21 ras peptide vaccination. Br J Cancer 1996; 74: 1828–1833.PubMedGoogle Scholar
  89. 88.
    Gjertsen M, Bjorheim J, Saeserdal I, Myklebust J, Gaudernack G. Cytotoxicity CD4(+) and CD8(+) T lymphocytes generated by mutant p21-ras (12 Val) peptide vaccination of a patient recognise 12 Val dependent nested epitopes present with in the vaccine peptide and kill autologous tumour cells carrying this mutant. Int J Cancer 1997; 72: 784–790.PubMedGoogle Scholar
  90. 89.
    McCarty TM, Liu XP, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JDI. Targeting of p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58: 2601–2605.PubMedGoogle Scholar
  91. 90.
    Peiper M, Goedegbuure PS, Eberlein TJ. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells. Surgery 1997; 122: 235–241.PubMedGoogle Scholar
  92. 91.
    Alters SE, Gadea JR, Philip R. Immunotherapy of cancer-generation of CEA specific cytotoxic T lymphocytes using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 1997; 417: 519–524.PubMedGoogle Scholar
  93. 92.
    Takebayashi H, Oida H, Fujisawa K, Yamaguchi M, Hikida T, Fukumoto M, et al. Hormone-induced apoptosis by Fasnuclear receptor fusion proteins: Novel biological tools for controlling apoptosis in vivo. Cancer Res 1996; 56: 4164–4170.PubMedGoogle Scholar
  94. 93.
    Kawaguchi Y, Takebayashi H, Kakizuka A, Arii S, Kato M, Imamura M. Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines. Cancer Lett 1997; 116: 53–59.PubMedGoogle Scholar
  95. 94.
    Ungefroren H, Voss M, Jansen M, Roeder C, Hennebruns D, Kremer B, et al. Human pancreatic carcinomas express Fas and Fas-ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 58: 1741–1749.PubMedGoogle Scholar
  96. 95.
    MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 1998; 95: 3655–3660.PubMedGoogle Scholar
  97. 96.
    Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997; 21: 1–12.PubMedGoogle Scholar
  98. 97.
    Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of matrix metalloproteinase-3 is an extra-cellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 9352–9360.PubMedGoogle Scholar
  99. 98.
    Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitors of metalloproteinase-1, 2 or 3 over-expression in rat vascular smooth muscle cell invasion, proliferation and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101: 1478–1487.PubMedGoogle Scholar
  100. 99.
    Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by over-expression of TIMP-3. Br J Cancer 1999; 79: 1347–1355.PubMedGoogle Scholar
  101. 100.
    Ahonen M, Baker AH, Kahori V-M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58: 2310–2315.PubMedGoogle Scholar
  102. 101.
    Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, et al. Suppression of in vivo tumour growth and induction of suspension cell death by tissue inhibitor of matrix metalloproteinase TIMP-3. Carcinogenesis 1996; 17: 1805–1811.PubMedGoogle Scholar
  103. 102.
    Fominaya J, Uherek C, Wels W. A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor. Gene Ther 1998; 5: 521–530.PubMedGoogle Scholar
  104. 103.
    Chen JB, Gamou S, Takayanagi A, Ohtake Y, Ohtsubo M, Shimizu N. Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor anti-bodies: improved immunogene approach. Cancer Gene Ther 1998; 5: 357–364.PubMedGoogle Scholar
  105. 104.
    Uherek C, Fominaya J, Wels W. A modular DNA carrier protein based on the structure of the diphtheria toxin mediates target cell-specific gene delivery. J Biol Chem 1998; 273: 8835–8841.PubMedGoogle Scholar
  106. 105.
    Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Wadhwa MS, et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum Gene Ther 1998; 9: 2083–2099.PubMedGoogle Scholar
  107. 106.
    Farwood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, et al. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994; 31(716): 23–34.Google Scholar
  108. 107.
    Schmid RM, Weidenbach H, Yamagushi H, Luhrs H, Liptay S, Adler G. Direct gene transfer into the rat pancreas using DNA-liposomes. Eur J Clin Invest 1998; 28: 220–226.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 1999

Authors and Affiliations

  • M. J. Humphreys
    • 1
  • W. Greenhalf
    • 1
  • J. P. Neoptolemos
    • 1
  • P. Ghaneh
    • 1
  1. 1.Department of SurgeryUniversity of Liverpool, Royal Liverpool University HospitalLiverpoolUK

Personalised recommendations